• Phase 1 trial will eval­u­ate Actimab-M in treating patients with multiple myeloma who are unresponsive to cur­rently avail­able ther­a­pies
• Clinical trial ini­ti­ated at Texas Oncology - Baylor Charles A. Sammons Cancer Center in Dallas, TX to be conducted by Principal Investigator and Trial Sponsor, Dr. Yair Levy
• Clinical pipe­line now in­cludes Iomab-B pivotal Phase 3 trial, Actimab-A Phase 2 trial and Actimab-M  Phase 1 trial

New York, NY (Press Release) -- Actinium Pharma­ceu­ticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a bio­pharma­ceu­tical …